[go: up one dir, main page]

WO1999064050A8 - Novel potassium channel drugs and their uses - Google Patents

Novel potassium channel drugs and their uses

Info

Publication number
WO1999064050A8
WO1999064050A8 PCT/US1999/012777 US9912777W WO9964050A8 WO 1999064050 A8 WO1999064050 A8 WO 1999064050A8 US 9912777 W US9912777 W US 9912777W WO 9964050 A8 WO9964050 A8 WO 9964050A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
ligands
channel
relates
channels
Prior art date
Application number
PCT/US1999/012777
Other languages
French (fr)
Other versions
WO1999064050A9 (en
WO1999064050A1 (en
Inventor
John R Jacobsen
Donna Eastman
John H Griffin
Original Assignee
Advanced Medicine Inc
John R Jacobsen
Donna Eastman
John H Griffin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc, John R Jacobsen, Donna Eastman, John H Griffin filed Critical Advanced Medicine Inc
Priority to EP99927330A priority Critical patent/EP1086063A1/en
Priority to CA002318745A priority patent/CA2318745A1/en
Priority to AU44264/99A priority patent/AU4426499A/en
Priority to JP2000553118A priority patent/JP2002517466A/en
Publication of WO1999064050A1 publication Critical patent/WO1999064050A1/en
Publication of WO1999064050A8 publication Critical patent/WO1999064050A8/en
Publication of WO1999064050A9 publication Critical patent/WO1999064050A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to novel multibinding compounds that bind to potassium (K+) channels and modulate their activity. The compounds of this invention comprise 2-10 K+ channel ligands covalently connected by a linker or linkers, wherein the ligands in their monovalent (i.e., unlinked) state bind to one or more types of K+ channel. The manner of linking the ligands together is such that the multibinding agents thus formed demonstrate an increased biologic and/or therapeutic effect as compared to the same number of unlinked ligands made available for binding to the K+ channel. The invention also relates to methods of using such compounds and to methods of preparing them. The compounds of this invention are particularly useful for treating diseases and conditions of mammals that are mediated by K+ channels. Accordingly, this invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
PCT/US1999/012777 1998-06-08 1999-06-07 Novel potassium channel drugs and their uses WO1999064050A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99927330A EP1086063A1 (en) 1998-06-08 1999-06-07 Novel potassium channel drugs and their uses
CA002318745A CA2318745A1 (en) 1998-06-08 1999-06-07 Novel potassium channel drugs and their uses
AU44264/99A AU4426499A (en) 1998-06-08 1999-06-07 Novel potassium channel drugs and their uses
JP2000553118A JP2002517466A (en) 1998-06-08 1999-06-07 Novel potassium channel drugs and their uses

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US9306898P 1998-07-16 1998-07-16
US11386498P 1998-12-24 1998-12-24
US60/088,465 1998-12-24
US60/113,864 1998-12-24
US60/093,068 1998-12-24

Publications (3)

Publication Number Publication Date
WO1999064050A1 WO1999064050A1 (en) 1999-12-16
WO1999064050A8 true WO1999064050A8 (en) 2000-02-24
WO1999064050A9 WO1999064050A9 (en) 2000-04-20

Family

ID=27375970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012777 WO1999064050A1 (en) 1998-06-08 1999-06-07 Novel potassium channel drugs and their uses

Country Status (7)

Country Link
EP (1) EP1086063A1 (en)
JP (1) JP2002517466A (en)
AR (1) AR015310A1 (en)
AU (1) AU4426499A (en)
CA (1) CA2318745A1 (en)
SG (1) SG80037A1 (en)
WO (1) WO1999064050A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019067C1 (en) * 2000-04-18 2001-10-04 Lohmann Therapie Syst Lts Transdermal plaster comprising dofetilide, is useful for treatment of cardiovascular disorders
CA2426666A1 (en) * 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
CA2433354A1 (en) * 2000-12-29 2002-07-25 Neogenesis Pharmaceuticals, Inc. Affinity selection-based screening of hydrophobic proteins
US9782488B2 (en) 2007-03-12 2017-10-10 Nektar Therapeutics Oligomer-beta blocker conjugates
NZ588623A (en) 2008-04-17 2012-11-30 Sanofi Aventis Use of a medicament containing dronedarone with food for preventing cardiovascular hospitalization
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE152917T1 (en) * 1990-09-28 1997-05-15 Neorx Corp POLYMERIC CARRIER FOR THE RELEASE OF COVALENTLY BONDED ACTIVE SUBSTANCES
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support

Also Published As

Publication number Publication date
CA2318745A1 (en) 1999-12-16
AR015310A1 (en) 2001-04-18
WO1999064050A9 (en) 2000-04-20
SG80037A1 (en) 2001-04-17
AU4426499A (en) 1999-12-30
EP1086063A4 (en) 2001-03-28
WO1999064050A1 (en) 1999-12-16
EP1086063A1 (en) 2001-03-28
JP2002517466A (en) 2002-06-18

Similar Documents

Publication Publication Date Title
WO1999063930A3 (en) Novel angiotensin receptor modulators and their uses
AU3057297A (en) Targeted combination immunotherapy of cancer
WO2002000194A3 (en) Polymeric micelle compositions
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
BG101290A (en) New promedicaments for the therapy of tumours and inflammatory diseases
WO2000066175A3 (en) Conjugates as therapies for cancer and prostate diseases
BR9914360A (en) N-aralkylaminotetralins as ligands for neuropeptide receptor yy5
ATE330967T1 (en) PEPTIDE COMPOUNDS BINDING TO HER2
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
WO2000016764A3 (en) Pharmaceutical compositions comprising derivatives of sulphur acids
DE69939036D1 (en) PEG conjugates of LHRH analogs
CA2372053A1 (en) Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1242115A4 (en) Chemically-programmable immunity
WO1998046270A3 (en) Polymeric conjugates polyvalently presenting an agent for therapy
ES2160643T3 (en) COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF.
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
WO1999064050A8 (en) Novel potassium channel drugs and their uses
WO2000078796A3 (en) Labeled neurotensin derivatives with improved resistance to enzymatic degradation
WO2000061551A3 (en) Pyrimidine-2-one derivatives as integrin receptor ligands
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
BR0016669A (en) Compound and pharmaceutical composition
FR2702481B1 (en) New soluble human Fc-gamma III receptors, their preparation process, the pharmaceutical compositions containing them, their application as medicaments and their diagnostic application.
ES2183346T3 (en) CONJUGATED BIS-PHOSPHONATE SYSTEMS WITH RENTAL REMAINS THAT HAVE ANTITUMORAL ACTIVITY.
TW202535936A (en) Antibodies targeting liv-1 and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999927330

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 50/99 UNDER (81) ADD "AE, ZA"

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/24-24/24, DRAWINGS, REPLACED BY NEW PAGES 1/23-23/23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 505889

Country of ref document: NZ

ENP Entry into the national phase in:

Ref document number: 2318745

Country of ref document: CA

Ref country code: CA

Ref document number: 2318745

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 44264/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000/04564

Country of ref document: ZA

Ref document number: 200004564

Country of ref document: ZA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 553118

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999927330

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999927330

Country of ref document: EP